SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Directorate

14 Jun 2012 07:00

RNS Number : 3333F
Consort Medical PLC
14 June 2012
 



 

14 June 2012

 

Consort Medical plc

 

DIRECTORATE

 

Consort Medical plc announces the appointment of Steve Crummett and Ian Nicholson as Non-executive Directors of the Company, effective immediately, and Richard Cotton as Group Finance Director, and as an Executive Director, with effect from 25th June 2012.

 

Consort Medical plc also announces the retirement of Chris Banks and Jim Dick as Non-executive Directors. They will step down at the Company's AGM on 30 August 2012. Toby Woolrych, currently Group Finance Director, has decided to leave the Company, and will step down on 29th June 2012, after a handover with his successor.

 

Chris Banks was appointed as a Non-executive Director in April 2006. He chairs the Audit Committee and is a Member of the Nomination Committee. Jim Dick, who was also appointed as a Non-executive Director in April 2006, chairs the Corporate and Social Responsibility Committee, and is a member of the Remuneration, Audit and Nomination Committees. Toby Woolrych was appointed as Group Finance Director in October 2008.

 

Steve Crummett is Group Finance Director of Filtrona plc, a FTSE 250 company, having been appointed to the role in 2008. Filtrona is a leading international supplier of speciality plastic, fibre and foam products. From 2003 to 2006, Steve was Group Director, Mergers & Acquisitions of the FTSE 100 company Exel plc. Steve qualified as a Chartered Accountant with Arthur Andersen. He will Chair the Audit Committee, and join the Nomination Committee.

 

Ian Nicholson has been Chief Executive of Chroma Therapeutics Limited, a drug discovery and development company since 2004. He is Chairman of Bioventix Ltd, a diagnostics company, and a Non-executive Director of Symphogen A/S, an antibody therapeutics company. From 2000 to 2004 Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK's largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. He will join the Nomination Committee.

 

Richard Cotton, a Chartered Management Accountant, has been appointed Group Finance Director of Consort Medical with effect from 25 June 2012. From 2008 to 2011 he was Group Finance Director of Vitec Group plc, from 2005 to 2008 Group Finance Director at Wagon plc (Wagon plc entered administration on 10th December 2008), and from 2001 to 2005 Group Finance Director of McLeod Russell plc.

 

Dr Peter Fellner, Chairman of Consort Medical, said:

 

"The Board would like to thank Chris, Jim and Toby for their valuable contributions during their tenures as Directors of the Company, and wish them well for the future.

 

"We warmly welcome the appointment of Steve, Ian and Richard to the Board. They all bring substantial and wide ranging experience and we look forward to working with them as we grow Consort for the benefit of our stakeholders."

 

Consort confirms that there are no further disclosures to be made under Rule 9.6.13 of the Listing Rules.

 

 

Enquiries:

 

Consort Medical plc

Tel: +44 (0) 1442 867920

Jonathan Glenn, Chief Executive Officer

Toby Woolrych, Group Finance Director

Brunswick Group LLP

Tel: +44 (0) 20 7404 5959

Jon Coles/Justine McIlroy/Amie Gramlick

 

 

Consort Medical plc is a leader in medical devices for inhaled drug delivery, self-injection and anaesthesia. The Group develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals.

 

Consort Medical's Bespak division develops and manufactures drug delivery devices and diagnostic disposable devices, including metered dose inhaler valves, actuators, compliance aids, dry powder devices, and autoinjectors. The King Systems division develops and manufactures disposable devices for anaesthetists and emergency medical practitioners, including video laryngoscopes, disposable facemasks, breathing circuits and laryngeal tubes. The Group has facilities in Kings Lynn, Cambridge, Nelson and Hemel Hempstead in the UK, and Indianapolis, Indiana and Kent, Ohio in the US. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT).

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAFJMPTMBJBBRT
Date   Source Headline
15th Jun 20123:12 pmRNSDirector/PDMR Shareholding
14th Jun 20127:00 amRNSDirectorate
14th Jun 20127:00 amRNSPreliminary Results
6th Jun 20121:57 pmRNSBlocklisting Interim Review
1st May 201210:21 amRNSTotal Voting Rights
30th Apr 20127:00 amRNSFDA Approval Proprietary Integrated Dose Counter
20th Apr 201210:54 amRNSHolding(s) in Company
16th Apr 201211:37 amRNSBlocklisting Interim Review
28th Mar 20124:36 pmRNSHolding(s) in Company
22nd Mar 20129:58 amRNSAnnual Information Update
20th Mar 20124:25 pmRNSReplacement Interim Management Statement
20th Mar 20121:07 pmRNSInterim Management Statement
1st Mar 20129:00 amRNSTotal Voting Rights
17th Feb 201210:09 amRNSHolding(s) in Company
23rd Jan 20129:45 amRNSBlocklisting Interim Review
13th Dec 20112:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20111:34 pmRNSBlocklisting Interim Review
1st Dec 20117:00 amRNSInterim results for the six months ended 31/10/11
19th Oct 20114:03 pmRNSHolding(s) in Company
17th Oct 20113:13 pmRNSHolding(s) in Company
14th Oct 20119:39 amRNSBlocklisting Interim Review
7th Oct 201112:13 pmRNSHolding(s) in Company
5th Oct 20114:47 pmRNSHolding(s) in Company
4th Oct 20117:00 amRNSSecond Nasal Drug Delivery Contract
27th Sep 20114:33 pmRNSHolding(s) in Company
26th Sep 20113:01 pmRNSHolding(s) in Company
2nd Sep 201110:21 amRNSTotal Voting Rights
1st Sep 20112:50 pmRNSResult of AGM
1st Sep 20112:47 pmRNSDirectorate Change
1st Sep 201112:40 pmRNSInterim Management Statement
1st Sep 20117:00 amRNSNasal Drug Delivery Contract
24th Aug 20114:35 pmRNSHolding(s) in Company
2nd Aug 20111:51 pmRNSDirector/PDMR Shareholding
2nd Aug 20111:47 pmRNSDirector/PDMR Shareholding
28th Jul 20119:14 amRNSAnnual Financial Report
20th Jul 20117:00 amRNSFurther re Investment in Atlas Genetics
30th Jun 20111:58 pmRNSTotal Voting Rights
24th Jun 20119:06 amRNSHolding(s) in Company
21st Jun 201112:33 pmRNSBlocklisting Interim Review
16th Jun 20117:00 amRNSPreliminary results for the year ended 30/04/11
2nd Jun 20117:00 amRNSBlocklisting Interim Review
10th May 20119:27 amRNSHolding(s) in Company
14th Apr 201110:20 amRNSBlocklisting Interim Review
4th Apr 201110:29 amRNSHolding(s) in Company
1st Apr 20111:51 pmRNSHolding(s) in Company
23rd Mar 20112:04 pmRNSAnnual Information Update
14th Mar 20117:00 amRNSInterim Management Statement
15th Feb 20114:14 pmRNSHolding(s) in Company
9th Feb 201111:15 amRNSDirectorate Change
7th Feb 20117:00 amRNSPartners with Atlas Genetics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.